Federal contract award
75N98023F00084
NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH OLAO |
| NAICS | 541990 — All Other Professional, Scientific, and Technical Services |
| PSC | R499 — Other Professional Services |
| Parent award / vehicle | 75N98020D00086 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $3.4M |
| Current contract value | $3.4M |
| Potential contract value / ceiling | $3.4M |
| Start date | Sep 30, 2023 |
| Current end date | Aug 31, 2028 |
| Potential end date | Aug 31, 2028 |
| Latest award activity | Jun 23, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 23, 2026 | P00005 | $0 | NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE S4 GUIDEHOUSE DIGITAL TO# 252 NIAID |
| Mar 27, 2026 | P00004 | $0 | NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE S4 GUIDEHOUSE DIGITAL TO# 252 NIAID |
| Mar 29, 2025 | P00003 | $0 | NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE S4 GUIDEHOUSE DIGITAL TO# 252 NIAID |
| Sep 23, 2024 | P00002 | $291.7K | NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE |
| Sep 29, 2023 | P00001 | $0 | NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE |
| Sep 18, 2023 | 0 | $3.1M | NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), UNIVERSAL INFLUENZA VACCINE, PHASE II CLINICAL TRIAL, SUPPORT SERVICE |
Estimated positioning window
Aug 31, 2027 – Feb 29, 2028
75/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 75/100. Available recorded signals: 70 points.
- Contract end 2028-08-31 (669 days from calculation)
- +25 points
- 285 historical awards in this buyer and category group
- +15 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2026-06-23
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.